Tuesday, 18 Dec 2018

You are here

Defining Refractory RA by Biologic Use

A study from the  British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).

Their study of 13,502 patients from the registry included RA patients who initially started a tumour necrosis factor inhibitor (TNFi) between 2001 to 2014.  They defined bDMARD refractory patients based on the need to switch to a third class of bDMARD.

They found that 867 of 13 502 (6%) patients were bDMARD refractory and that this took nearly 8 years to get to their third bDMARD class.

Interestingly, 6.7% of those enrolled 2001–2008 were bDMARD refractory disease and took a longer median time (median 8.4 years) to achieve this status compared to more recent enrollees. Of those enrolled between 2011–2014, 4.8% became bDMARD refractory, but in a much shorter time of 2.0 years; suggesting physicians have become more likely to cycle bDMARDs. 

For example, bDMARD refractory patients were remained on their first TNFi for a median of 3.9 years - longer in the earlier cohort compared to the more recent cohort (4.4 years vs 0.8 years, respectively).  Reasons for 1st TNFi discontinuation included ineffectiveness (52%), adverse events (24%), and other reasons (3%) such as injection-related problems or family planning). The reason for stopping the TNFi was not recorded in 21% of patients.

Multivariate analysis showed that bDMARD refractory disease patients were more lkely to be women, younger age, shorter disease duration, higher patient global assessment, higher Health Assessment Questionnaire score, current smokers, obesity and greater social deprivation.

Patterns of biologic use revealed that after the initial TNFi, most changed to a second TNFi (55%), especially in the 2001-2008 cohort (59%), but less so in the modern 2011-2014 cohort where only 19% chose a second TNFi.  The vast majority (83%) of 2nd bDMARD changes went to B cell inhibition (i.e., rituximab).  Third bDMARD changes preferred IL-6 inhibitors (54%) over T cell costimulation inhibitors (24%).  This is observational data. The authors note that these therapeutic choices  largely reflected the order in which these drugs became available in the UK. 

EULAR has developed a ‘difficult-to-treat’ RA task force to study this issue, as there is no accepted definition of bDMARD refractory RA. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Kallikrein Inhibitor Lanadelumab Prevents Hereditary Angioedema Attacks

Hereditary angioedema is a rare autosomal dominant disorder due to C1 inhibitor deficiency (type I) or dysfunction (type II) that leads to dysregulated plasma kallikrein activity, excess bradykinin production, and unpredictable potentially life-threatening recurrent angioedema attacks.

FDA Approves Biosimilar Rituximab for NHL, not RA

The U.S. Food and Drug Administration on Wednesday approved Celltrion biosimilar of rituximab called Truxima; previously called CT-P10, now generically labeled as rituximab-abbs. This is the first biosimilar to the Rituxan currently approved to treat non-Hodgkin’s lymphoma. Truxima is not approved for use in rheumatoid arthritis, vasculitis, pemphigus vulgaris or chronic lymphocytic leukemia.

First FDA Approved Drug for HLH

The first drug specifically for primary hemophagocytic lymphohistiocytosis (HLH) was approved today, the FDA announced.

Emapalumab (Gamifant), manufactured by Novimmune SA, may be used in all patients (including newborns and older children) "who have refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy," the FDA said.

Should Immunoglobulins be Monitored with Rituximab Use?

Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients.

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.